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Abstract 
Aims: Vitamin D deficiency is very common in elderly populations throughout the world and 
seems to be related with poorer muscle strength, function and risk of falls. This review aims 
to summarize the available data about the vitamin D role in this matter. 
Methods: A search was conducted in the Pubmed database for articles with the following 
terms: “muscle strength”, “body sway”, “balance”, “risk of fall”, “vitamin D”, “elderly”, 
“cholecalciferol” and “ergocalciferol”. Further articles were obtained thru reference lists. 
Results: Observational studies point to a relationship between serum 25-hydroxyvitamin D 
levels and muscle strength, neuromuscular function and falls. Concentrations ≥ 40 nmol/L or 
≥ 25 nmol/L were associated with better short physical performance battery test and ≥ 50 
nmol/L with handgrip strength. Levels below 25 nmol/L had worst stride-to-stride variability 
of stride test and diminished handgrip strength overtime. One study found an association with 
falls while two studies found no association. 
Randomized controlled trials convey contradictory results. Muscle strength was only seen to 
be related with treatment in women with 25-hydroxyvitamin D levels below 60 nmol/L and 
with lowest strength. Associations were found with body sway, timed up and go test and 
preferred walking speed. In terms of falls a reduction from 19% to 49% was seen in studies 
but others didn’t achieve statistical significance and one even showed adverse effect when 
very high doses were used. 
A systematic review concluded that randomized trials with low 25-hydroxyvitamin D baseline 
levels showed a positive effect on muscle function. Several meta-analysis attribute a positive 
effect of vitamin D supplementation on falls and one showed a tendency without statistical 
significance. 
Conclusions: Vitamin D, especially when combined with calcium and in vitamin D deficient 
elderly, provides some fall prevention. Its effects on muscle strength and function are less 
consistent. 
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List of abbreviations 
 
25(OH)D – 25-hydroxyvitamin D 
LASA – Longitudinal Aging Study Amesterdam 
OR – Odds Ratio 
OPRA – Malmo Osteoporosis Prospective Risk Assessment 
OPUS – Osteoporosis and Ultrasound Cohort 
RCT – Randomized controlled trial 
RR – Relative Risk 
SPPB – Short Physical Performance Battery 
STV – Stride-to-Stride variability of stride time 
TCS – Timed Chair Stand 
TUG – Timed Up and Go test 
UVB – Ultraviolet B light 
VDR – Vitamin D Receptor   
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Introduction 
Vitamin D is a generic term used to describe the molecules ergocalciferol (also known 
as vitamin D2) and cholecalciferol (or vitamin D3). 1 The main source of vitamin D is 
believed to be the sunlight (thru UVB radiation) but if it is enough for optimal levels to be 
achieved in human beings, is still a controversial subject.2 A large number of studies 
concluded that vitamin D deficiency is highly prevalent in North America3 and Europe4,5. 
Prevalence is higher in elderly populations6 and in housebound7 or institutionalized8 older 
individuals. 
The incidence of falls in the elderly population is approximately 30% per year9,10 and 
within this group, the falls result in a fracture in 7,7%10. With the aging of the world 
population, the prevention of this type of falls should be addressed to diminish these numbers. 
Vitamin D receptor (VDR) KO mice are associated with type I and type II muscle 
fibers atrophy, poor musculoskeletal performance and changes in gait. Rats in which vitamin 
D deficiency was induced also showed altered muscle function.11 
In humans, vitamin D deficiency is characterized by muscle weakness, muscle pain 
and impaired gait12,13, so the relationship between vitamin D serum levels and muscle 
function seems to exist. Several studies address this relationship and will be discussed in this 
paper. 
The aim of this study is to give a global perspective on the available data regarding 
vitamin D serum levels and its association with muscle strength, coordination and risk of fall 
in the elderly population.  
 
Materials and Methods 
A search was conducted in the Pubmed database for publications in the English, 
Spanish and Portuguese languages, with abstracts available and containing the following 
search terms: “muscle strength”, “body sway”, “balance”, “risk of fall”, “vitamin D”, 
“elderly”, “cholecalciferol” and “ergocalciferol”. Additional studies were identified searching 
reference lists. The studies with populations below 60 years of age, focusing on animals, 
related with fractures and with unavailable full article access were excluded. 
 
Results 
 A total of 26 articles were used in this review, of which one was a systematic review 
and four were meta-analysis. 
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In a study conducted with 4100 ambulatory subjects aged ≥ 65 years, 49% woman, 
higher serum concentrations of 25-hydroxyvitamin D (25(OH)D) were associated with better 
results in musculoskeletal function. The higher quintile showed an average improvement of 
5.6% in the 8-foot walk test and 3.9% in the sit-to-stand test, when compared with the lowest 
quintile.14  
A cross-sectional study, using data from the InCHIANTI study, including 976 subjects 
aged ≥ 65 years, assessed physical performance using a short physical performance battery 
(SPPB), consisting of walking speed, ability to stand from a chair and ability to maintain 
balance in progressively more challenging positions. Handgrip strength was measured with a 
handheld dynamometer. Serum levels of 25(OH)D <25 nmol/L were associated with lower 
SPPB scores and values below 50 nmol/L were associated with lower handgrip strength.15 
Another cross-sectional study examined the association between stride-to-stride 
variability of stride time (STV) and the serum levels of 25(OH)D in 411 subjects above 65 
years of age. 25(OH)D levels below 10 ng/mL (25 nmol/L) were significantly associated with 
higher STV and low lower limb proprioception score. No changes were observed in handgrip 
strength.16 
In the OPRA study, 986 women aged 75 years old, were examined for balance, muscle 
strength and gait speed. The results showed inferior gait speed, poorer balance and lower knee 
extension strength for subjects with 25(OH)D levels below 30 ng/mL (75 nmol/L).17 
In a cohort of 109 men and 131 women aged 65 years of age or older and community 
dwelling, no significant associations were found between the levels of serum 25(OH)D and 
muscle strength in men. In women, after adjustment for confounders, low levels were 
associated with higher handgrip force.18 
Using data from the LASA study, Visser et al. concluded that low 25(OH)D levels 
(<25 nmol/L) were associated with higher prevalence of loss of grip strength in the elderly 
(OR 2.57, 95% CI 1.40-4.70).19 
In a cross-sectional and longitudinal analysis, Dam and co-workers concluded that 
women with lower 25(OH)D levels had poorer results in the Timed up and Go (TUG) and 
Timed Chair Stand (TCS) tests. In the prospective analysis, women with levels ≤ 80 nmol/L, 
had a mean percentage reduction of 20% in the TUG and TCS tests when compared with 
women with levels ≥ 115 nmol/L. No association was found for males.20 
A sample of 1234 individuals aged 65 years or older, of which 600 are men and 634 
women, were assessed by three performance tests during a three year follow up: walking test, 
chair stands and tandem stand. These three tests were combined in a performance score.  
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Participants with serum 25(OH)D levels below 10 ng/mL scored lower on all tests when 
compared with subjects with levels ≥ 30 ng/mL. Participants with levels below 20 ng/mL had 
significantly lower scores for physical performance and higher odds for decline in physical 
performance.21 
A 16 week, double-blind study examined the effects of a weekly dose of 8400 IU 
vitamin D3 on postural stability, muscle strength and safety compared with placebo, in a 
sample population aged ≥ 70 years old, ambulatory and with serum 25(OH)D concentrations 
between 6 ng/mL and 20 ng/mL. Even though 25(OH)D levels increased significantly in the 
treatment group, no differences were found in body sway and in the SPPB score between the 
two groups. However, in a post hoc analysis, those individuals with mediolateral sway ≥ 0.46 
cm showed a significant reduction in the treatment group when compared with the placebo 
group.22 
In a prospective, randomized, double-blind, placebo controlled study, patients 
attending a falls clinic, aged over 65 years and with 25(OH)D levels ≤ 12µg/L were assessed 
with the following neuromuscular tests: aggregate functional performance time, chain 
reaction time, postural stability and quadriceps strength. Then they were randomized to 
receive 600000 IU of ergocalciferol or placebo. After six months the treatment group 
improved aggregate functional performance time by 2s versus the 6.6s decrease in the placebo 
group. In the chain reaction time the results were 15% improvement versus 3% decrease in 
the placebo group. Postural sway improved 13% in the treatment group and decreased 3% in 
the placebo. Muscle strength difference was not statistically different but with a tendency for 
less loss of strength in the treatment group.23 
In a 6 months randomized controlled trial (RCT), 113 institutionalized women over 70 
years of age received calcium and vitamin D supplementation and 56 also received whole 
body vibration. The preferred speed of 10 m walk and the TUG tests obtained significantly 
better performances in both groups. Fall risk did not change significantly in any group. 
However, results were better in the whole body vibration group.24 
In a RCT, 302 women aged between 70 and 90 years of age, with a plasma 25(OH)D 
concentration below 24 ng/mL, and with a history of at least one fall in the previous 12 
months were randomized to receive 1000 IU ergocalciferol per day or placebo during one 
year. All participants received 1000 mg/d calcium. Muscle strength was measured with a 
strain gauge and mobility with the TUG test. The vitamin D group showed significantly 
improved hip muscle strength in the subjects within the lower tertile of strength, and 17,5% 
improved TUG time in the participants with time longer than 12s.25 
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A systematic review including 16 RCTs concerning muscle function and performance, 
concluded that almost all studies observed an increase in 25(OH)D levels with treatment. A 
little less than half showed an improvement in muscle strength, reduced body sway, improved 
TUG test, increase in gait speed and improved aggregated measures of physical abilities. 
However, no beneficial effects were found for hand grip strength. The author also points out 
that all studies showing a beneficial effect included only participants with low vitamin D 
concentrations at baseline and that the studies are very heterogeneous in many aspects.26 
A study analyzing the association between vitamin D receptor gene polymorphisms 
and falls in the OPUS cohort concluded that no statistical difference existed between the 
serum levels of 25(OH)D and the incidence of falls.27 
An observational study including 9526 community-dwelling women aged 65 years and 
older examined the relationship between supplementation with vitamin D and neuromuscular 
function and falls incidence in a 4 year period. Grip strength, quadriceps strength, chair-stand 
time, gait speed and balance walk time were examined. Participants were asked if they had 
fallen in the last 4 months, every four months. They found no association between vitamin D 
supplement users and all neuromuscular function tests used. Higher concentrations of 
25(OH)D (≥26 ng/mL) were associated with poorer grip strength. No association was found 
between 25(OH)D concentrations and falls.28 
However, another observational study concluded that serum 25(OH) levels <10 ng/mL 
in a population aged ≥ 65 years, were associated with an increase in the incidence of recurrent 
falls. This association was particularly accentuated in the ≥ 65 - < 75 age range.29 
A RTC with a sample comprised by 112 women aged 60 years or older and in a long-
stay geriatric unit in Switzerland, compared treatment with vitamin D (800 IU/d) + calcium 
(1200 mg/d) vs calcium alone for 12 weeks. 50% of the women had baseline 25(OH)D levels 
below 30 nmol/L. The results showed a reduction of 49% in the number of falls per person in 
the treatment group. There was no statistically significant difference in the number of fallers. 
Musculoskeletal function was a secondary endpoint and also improved in the treatment group 
(knee flexor strength, knee extensor strength, grip strength, TUG test).30 
Another RCT with a sample of 302 community-dwelling women aged 70 to 90 years 
living in Australia, tested the effects of treatment with 1000 IU/d ergocalciferol + 1000 mg/d 
calcium vs placebo + 1000 mg/d calcium on the risk of falls. Only patients with 25(OH)D 
levels below 24 ng/mL and at least one fall in the previous year were included. The 
ergocalciferol group showed a 19% decrease in the risk of falling. This decrease was 
particularly accentuated in winter/spring. No effects were found in multiple fallers.31 
7 
 
Two hundred and five patients aging 65 years or older and admitted to a geriatric 
medical unit were randomized to receive 800 IU vitamin D3 + 1200 mg calcium or just 1200 
mg calcium in a RCT. Falls and fractures were registered until discharge. 85% of the patients 
had a previous history of falls and the median length of stay in the unit was 30 days. No 
statistically significant changes were detected in terms of risk of fall, total falls or fractures 
comparing the treatment group and the control group. The serum levels of 25(OH)D didn’t 
increase in a significant manner in the treatment group.32  
M. Law et al., in a RCT conducted in 118 Britain care homes and with 3717 
participants, determined the effects of supplementation with 2.5 mg ergocalciferol every 3 
months. No placebo was given to the control group. Falls were recorded by the care home 
staff. No reduction in falls was found with this supplementation, even thou 25(OH)D levels 
increased.33 
A double-blind, placebo-controlled trial including 2256 community-dwelling women 
with age above 70 years were randomized to receive 500000 IU of cholecalciferol or placebo, 
once a year for a period of 3 to 5 years. The study aimed to improve patient’s adherence to 
vitamin D supplementation and reduce falls and fractures. The cumulative incidence of first 
fall was higher in the vitamin D group, with a hazard ratio of 1.16, p=0.003. A post-hoc 
analysis found a higher incidence of falls in the vitamin D group in the first 3 months 
following the annual dose. The median 25(OH)D level at baseline was 49 nmol/L whereas at 
1 month after the dose was 120 nmol/L, with 82% above 100 nmol/L.34 
Glendenning et al. tested the effects of treatment with 150000 IU of cholecalciferol 
administered every three months combined with lifestyle advices vs placebo and lifestyle 
advices, on falls, mobility and muscle strength in 686 community dwelling women aged 
above 70 years. Falls were self-registered in a diary. During the 9 months period of the study, 
the OR for the treatment group compared with the placebo group was 1.11 (95% CI 0.80-
1.56) for at least one fall and 1.58 (95% CI 0.83-2.99) for multiple falls. Hand grip strength 
and TUG test, which were a secondary endpoint, didn’t differ significantly in any of the 
groups.35 
A meta-analysis comprising only double-blind RCTs assessing vitamin D treatment 
and falls (as a primary or secondary outcome) and with a fall definition well defined, 
compiled data from 5 studies. The corrected odds ratio was 0.78 (95% CI, 0.64-0.92), 
suggesting a reduced risk of falls by 22%. When 5 other studies that didn’t meet the initial 
criteria were added the reduction was attenuated, suggesting a reduction in the risk of fall with 
vitamin D supplementation of 13%.36 
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Another meta-analysis including 9 studies (8 RCTs and one prospective study) pooled 
data relative to vitamin D3 treatment (with or without calcium) and the risk of fall. Vitamin 
D3 daily doses ranged from 300 to 800 IU. The pooled RR was 0.88 (95% CI 0.78-1.00), 
showing a trend to the prevention of falls.37 
Bischoff-Ferrari et al. conducted another meta-analysis including 10 RCTs regarding 
treatment with oral vitamin D (vitamin D2, vitamin D3 and active forms) and the prevention 
of falls in individuals of at least 65 years of age and a 3 months minimum follow-up. The 
results showed a pooled RR of 0.87 (95% CI 0.77 to 0.99) but with heterogeneity detected. 
After stratifying the studies into a low dose (200-600 IU) and high dose (700-1000 IU) 
vitamin D supplementation, heterogeneity was solved and the pooled RR was 1.10 (95% CI 
0.89 to 1.35) and 0.81 (95% CI 0.71 to 0.92), respectively. Moreover, 25(OH)D 
concentrations above 60 nmol/L resulted in a 23% fall reduction and levels below 60 nmol/L 
had no effect on fall rate. Also, in a subgroup analysis of the high dose vitamin D studies, 
relative risk reduction was 12% in vitamin D2 trials and 26% in vitamin D3, although this 
observation was not statistically significant (p=0.28).38 
A recent meta-analysis concerning vitamin D and its effect on falls, included 26 
randomized trials comparing vitamin D supplementation with no supplementation. Trials with 
calcitriol were excluded from the analysis. The results showed a statistically significant 
reduction in the risk of falls in the vitamin D treated group (OR 0.86 with a 95% CI of 0.77-
0.96). However, the I2 test detected substantial heterogeneity in the studies. In a subgroup 
analysis, a statistically significant relationship was found between vitamin D deficient and not 
deficient and between risk of fall and calcium co-administration. No relationship was found 
when the subgroups were tested for dose of vitamin D (at least 800 IU or greater than 600 
IU).39 
 
Discussion 
In the recent years a lot of literature involving vitamin D and its possible applications 
has been published. On the subject of muscle strength and neuromuscular coordination, the 
available studies show conflicting results. 
Cross-sectional studies14-17 present a positive interaction between serum 25(OH)D 
levels and better muscular function, assessed by various methods. This association was also 
apparent in both sexes14,15 and concentrations ≥ 40 nmol/L14 or ≥ 25 nmol/L for SPPB and ≥ 
50 nmol/L for handgrip strength15. On the other hand, a study16 only found an association 
between levels below 10 ng/mL (25 nmol/L) and STV. Only one study18 reported no 
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association in men and an inverse association for handgrip strength and low levels of 
25(OH)D in women, although the sample was small and the prevalence of vitamin D 
deficiency in the sample wasn’t know, only for the total cohort which included ages ranging 
from 21 to 93 years. 
Longitudinal studies supported this association when loss of grip strength was 
observed to be more pronounced in individuals with 25(OH)D levels below 25 nmol/L19,21 
and levels ≤ 80 nmol/L were associated with 20% reduction in TUG and TCS tests compared 
with levels ≥ 115 nmol/L in women20. Similarly with the study from Marantes et al, Faulkner 
and colleagues28 concluded that 25(OH)D levels had no relationship with neuromuscular 
function. However, dosage of supplementation was unknown and the population had higher 
levels at baseline. 
Randomized controlled trials also support these findings, however in a partial manner. 
Some find that body sway is improved but only when above 0.46 cm22 and no effect on 
muscle strength. Another23 positively relates vitamin D treatment and aggregate functional 
performance time, chain reaction time and body sway but failed to achieve statistically 
significant results in muscle strength. Other24 shows a positive relation with TUG test and 
preferred walking speed, but failed to achieve significance in terms of body sway. Concerning 
muscle strength, a statistically significant positive result was seen in women with 25(OH)D 
levels below 24 ng/mL (60 nmol/L) and lowest strength.25 
A systematic review26 concluded that almost half the included RCT had positive 
effects and that those were the ones with low baseline 25(OH)D levels, but also points that 
studies were heterogeneous. This review also included trials with populations below 60 years 
of age. 
Observational studies and the relation between vitamin D levels and falls have 
conflicting data. Some are positive29, others negative27,28. The positive one was aimed to a 
vitamin D deficient population and falls were assessed weekly. In the negatives falls were 
assessed yearly and every 4 months. 
RCT data, like observational, also conveys contradictory results. There are positive 
studies, reporting a positive relation ranging from 19% to as much as 49% decrease in falls 
per person30,31. There are also many tests showing no relation32,33,35 or even an adverse effect 
when very high doses of cholecalciferol were used34. 
This topic was highly reviewed in meta-analysis and those results tend to attribute a 
positive effect of vitamin D on fall risk. Some didn’t reach statistical significance but all 
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studies that targeted vitamin D deficient populations or/and high daily dose reached a positive 
association. 
Study heterogeneity is a major issue when analyzing the role of vitamin D and muscle 
strength, function and falls. Studies use different measuring methods for body sway and 
muscular function. Baseline 25(OH)D concentrations in the sample population also differ 
from study to study. To this matter also contribute the controversy around the vitamin D 
deficiency definition. Several different values for vitamin D deficiency have been proposed 
using different methods.40,41 Other confounding factor is 25(OH)D serum concentrations and 
its variability inter-laboratories.42 Some studies include males and females whereas others 
only females. Doses of vitamin D treatment are also different and even the type administered 
(vitamin D2 or vitamin D3). Different types of vitamin D might imply different results in 
25(OH)D concentration43. The study durations are also very different, ranging from 30 days 
to years. Falls assessing methods also vary, with some studies using self-report methods while 
others are reported by nursing home staff. 
A recent review11 arrived to very similar conclusions to those of this work. 
 
Conclusion 
Despite the heterogeneity in studies and the difficulty to compile data, vitamin D 
supplementation associated with calcium appears to be beneficial to older individuals, 
especially if vitamin D deficient and at doses above 800 IU/d, to prevent falls. 
In terms of muscle strength and function, there’s also a suggestion that 
supplementation might be beneficial, but larger and more standardized studies are necessary 
for safer conclusions to be made. 
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